Factors Guiding Therapy Choice: CAR T vs Bispecific Antibodies in Relapsed/Refractory Follicular Lymphoma

Panelists discuss how the decision between CAR T therapy and bispecific antibodies depends on multiple factors, including disease characteristics, treatment goals, and patient preferences. CAR T offers a one-time, potentially long-lasting remission, while bispecific antibodies provide a more flexible outpatient option. Understanding the distinctions in mechanism, logistics, and safety helps ensure each patient receives the therapy best suited to their needs.

Clinicians evaluate clinical readiness, access, and timing when recommending one approach over another. Patients who are fit for intensive therapy and can commit to the preparation and recovery process may be strong candidates for CAR T, whereas those who prefer ongoing, less invasive management might benefit more from bispecific antibodies.

Patient education and support are essential in guiding these decisions. Both therapies have distinct monitoring requirements, but shared goals—durable remission, safety, and quality of life—remain central. By aligning treatment with patient priorities, clinicians ensure that care remains compassionate, personalized, and evidence-based.